Herpes simplex virus and human papillomavirus genital infections: new and investigational therapeutic options

被引：5

作者：

Viera, Martha H. ^{[1
]}

Amini, Sadegh ^{[1
]}

Huo, Ran ^{[1
]}

Konda, Sailesh ^{[1
]}

Block, Samantha ^{[1
]}

Berman, Brian ^{[1
]}

机构：

[1] Univ Miami, Miller Sch Med, Dept Dermatol & Cutaneous Surg, Miami, FL 33136 USA

来源：

INTERNATIONAL JOURNAL OF DERMATOLOGY | 2010年 / 49卷 / 07期

关键词：

PLACEBO-CONTROLLED TRIAL; IMIQUIMOD 5-PERCENT CREAM; RANDOMIZED CLINICAL-TRIAL; RESIQUIMOD 0.01-PERCENT GEL; EXTERNAL ANOGENITAL WARTS; IMMUNE-RESPONSE MODIFIER; ORAL ACYCLOVIR TREATMENT; BLIND CONTROLLED-TRIAL; CONDYLOMATA ACUMINATA; RECURRENT HERPES;

D O I：

暂无

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100227 [皮肤病学];

摘要：

Human papillomavirus and Herpes simplex virus are the most common genital viral infections encountered in clinical practice worldwide. We reviewed the literature focusing on new and experimental treatment modalities for both conditions, based on to the evidence-based data available. The modalities evaluated include topical agents such as immune response modifiers (imiquimod, resiquimod, and interferon), antivirals (penciclovir, cidofovir, and foscarnet), sinecatechins, microbiocidals (SPL7013 gel, and PRO 2000 gel), along with experimental (oligodeoxynucleotides), immunoprophylactic, and immunotherapeutic vaccines.

引用

页码：733 / 749

页数：17

共 205 条

[1]

TREATMENT OF EXTERNAL GENITAL WARTS COMPARING CRYOTHERAPY (LIQUID-NITROGEN) AND TRICHLORACETIC ACID [J].

ABDULLAH, AN ;

WALZMAN, M ;

WADE, A .

SEXUALLY TRANSMITTED DISEASES, 1993, 20 (06) :344-345

[2]

ABEER A, 2007, EGYPT DERMATOL ONLIN, V3, P5

[3]

AHUMADAP M, 1977, THER GEGENWART, V116, P100

[4]

ALTOMARE GF, 1985, GIORN ITAL DERMAT V, V120, P41

[5]

Valacyclovir therapy to reduce recurrent genital herpes in pregnant women [J].

Andrews, WW ;

Kimberlin, DF ;

Whitley, R ;

Cliver, S ;

Ramsey, PS ;

Deeter, R .

AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2006, 194 (03) :774-781

[6]

[Anonymous], 2008, Med Lett Drugs Ther, V50, P15

[7]

Single-day, patient-initiated famciclovir therapy for recurrent genital herpes: A randomized, double-blind, placebo-controlled trial [J].

Aoki, FY ;

Tyring, S ;

Diaz-Mitoma, F ;

Gross, G ;

Gao, J ;

Hamed, K .

CLINICAL INFECTIOUS DISEASES, 2006, 42 (01) :8-13

[8]

Correlation between pretreatment levels of interferon response genes and clinical responses to an immune response modifier (Imiquimod) in genital warts [J].

Arany, I ;

Tyring, SK ;

Brysk, MM ;

Stanley, MA ;

Tomai, MA ;

Miller, RL ;

Smith, MH ;

McDermott, DJ ;

Slade, HB .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2000, 44 (07) :1869-1873

[9]

Topical imiquimod 5% cream in external anogenital warts: A randomized, double-blind, placebo-controlled study [J].

Arican, O ;

Guneri, F ;

Bilgic, K ;

Karaoglu, A .

JOURNAL OF DERMATOLOGY, 2004, 31 (08) :627-631

[10]

Local delivery of CpG oligodeoxynucleotides induces rapid changes in the genital mucosa and inhibits replication, but not entry, of herpes simplex virus type 2 [J].

Ashkar, AA ;

Bauer, S ;

Mitchell, WJ ;

Vieira, J ;

Rosenthal, KL .

JOURNAL OF VIROLOGY, 2003, 77 (16) :8948-8956

← 1 2 3 4 5 6 7 8 9 10 →